BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12942457)

  • 1. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.
    Jain AB; Venkataramanan R; Eghtesad B; Marcos A; Ragni M; Shapiro R; Rafail AB; Fung JJ
    Liver Transpl; 2003 Sep; 9(9):954-60. PubMed ID: 12942457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.
    Pea F; Tavio M; Pavan F; Londero A; Bresadola V; Adani GL; Furlanut M; Viale P
    Antivir Ther; 2008; 13(5):739-42. PubMed ID: 18771060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation.
    Schonder KS; Shullo MA; Okusanya O
    Ann Pharmacother; 2003 Dec; 37(12):1793-6. PubMed ID: 14632538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients.
    Vogel M; Voigt E; Michaelis HC; Sudhop T; Wolff M; Türler A; Sauerbruch T; Rockstroh JK; Spengler U
    Liver Transpl; 2004 Jul; 10(7):939-44. PubMed ID: 15237382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
    Hills-Nieminen C; Hughes CA; Houston S; Shafran SD
    Ann Pharmacother; 2009 Dec; 43(12):2117-20. PubMed ID: 19934385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.
    Barau C; Blouin P; Creput C; Taburet AM; Durrbach A; Furlan V
    Fundam Clin Pharmacol; 2009 Aug; 23(4):423-5. PubMed ID: 19709321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
    Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM
    Clin Pharmacol Ther; 2004 Apr; 75(4):310-23. PubMed ID: 15060509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
    van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report.
    Jain AK; Venkataramanan R; Fridell JA; Gadomski M; Shaw LM; Ragni M; Korecka M; Fung J
    Liver Transpl; 2002 Sep; 8(9):838-40. PubMed ID: 12200787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
    Guaraldi G; Cocchi S; Codeluppi M; Di Benedetto F; Bonora S; Motta A; Luzi K; Pecorari M; Gennari W; Masetti M; Gerunda GE; Esposito R
    Transplant Proc; 2006 May; 38(4):1138-40. PubMed ID: 16757288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.
    Bates DE; Herman RJ
    Ann Pharmacother; 2006 Jun; 40(6):1190-5. PubMed ID: 16720703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.